LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Search

Biogen Inc

Abrir

SetorSaúde

137.98 0.41

Visão Geral

Variação de preço das ações

24h

Atual

Mín

135.28

Máximo

137.65

Indicadores-chave

By Trading Economics

Rendimento

394M

635M

Vendas

215M

2.6B

P/E

Médio do Setor

13.46

35.69

EPS

3.02

Margem de lucro

23.995

Funcionários

7,605

EBITDA

457M

1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+21.72% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.9B

21B

Abertura anterior

137.57

Fecho anterior

137.98

Sentimento de Notícias

By Acuity

50%

50%

131 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Biogen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de set. de 2025, 18:25 UTC

Grandes Movimentos do Mercado

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 de set. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 de set. de 2025, 23:48 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

28 de set. de 2025, 23:45 UTC

Conversa de Mercado

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 de set. de 2025, 23:34 UTC

Conversa de Mercado

Oil Falls on Likely Technical Correction -- Market Talk

27 de set. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

26 de set. de 2025, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 de set. de 2025, 20:54 UTC

Ganhos

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 de set. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

26 de set. de 2025, 20:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 de set. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

26 de set. de 2025, 19:54 UTC

Conversa de Mercado

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 de set. de 2025, 19:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 de set. de 2025, 19:40 UTC

Ganhos

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 de set. de 2025, 19:24 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 de set. de 2025, 19:17 UTC

Conversa de Mercado

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 de set. de 2025, 19:15 UTC

Conversa de Mercado

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 de set. de 2025, 19:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

26 de set. de 2025, 19:03 UTC

Conversa de Mercado

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 de set. de 2025, 18:50 UTC

Conversa de Mercado
Ganhos

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 de set. de 2025, 18:36 UTC

Conversa de Mercado

Silver Closes Out Week With Strong Surge -- Market Talk

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 de set. de 2025, 17:54 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 de set. de 2025, 16:56 UTC

Conversa de Mercado
Ganhos

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 de set. de 2025, 16:41 UTC

Conversa de Mercado
Ganhos

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 de set. de 2025, 16:26 UTC

Ganhos

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Biogen Inc Previsão

Preço-alvo

By TipRanks

21.72% parte superior

Previsão para 12 meses

Média 167.2 USD  21.72%

Máximo 224 USD

Mínimo 118 USD

Com base em 26 analistas de Wall Street que oferecem metas de preço de 12 meses para Biogen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

26 ratings

12

Comprar

14

Manter

0

Vender

Pontuação Técnica

By Trading Central

118.15 / 121.17Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

131 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat